Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05985655 · ClinicalTrials.gov registry record · Phase 1
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
A Phase 1 study of Pancreatic Adenocarcinoma and Non-small Cell Lung Cancer (NSCLC), sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 230
- Enrollment target
- 12
- Study locations
NCT05985655 is a Phase 1 study of Pancreatic Adenocarcinoma and Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals. The registered enrollment target is 230 participants, below the 99,461-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 12 study locations across 4 states.
The verdict
NCT05985655, a Phase 1 study of Pancreatic Adenocarcinoma and Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 230 participants
- Enrollment target
- 12
- Study locations
Study Summary
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG GTAEXS617
- DRUG SoC
Study Locations (12)
Other
- GZA Ziekenhuizen - Campus Sint-Augustinus - Antwerp
- Clinique Universitaires Saint-Luc - Brussels
- Institute Jules Bordet - Brussels
- CHU Sart Tilman - Liège
- The Beatson West of Scotland Cancer Centre - Glasgow
- UCL Hospitals NHS Foundation Trust - London
- The Christie NHS Foundation Trust - Manchester
- Newcastle Upon Tyne NHS Foundation Trust - Newcastle upon Tyne
- Oxford University Hospitals NHS Foundation Trust - Oxford
Michigan
- START Midwest - Grand Rapids
Texas
- START San Antonio - San Antonio
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05985655
The ClinicalTrials.gov registry entry for NCT05985655 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,461-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which GTAEXS617 is the first listed.
NCT05985655 reports 12 study locations spanning 4 distinct geographic areas - top geographies include Other, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT05985655 about?
NCT05985655 is a clinical study titled "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors". The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
What is the current status of trial NCT05985655?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2023-07-06. Estimated completion is 2028-05.
What conditions does trial NCT05985655 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Head and Neck Squamous Cell Carcinoma (HNSCC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC).
What interventions are being tested in trial NCT05985655?
The interventions under investigation include: GTAEXS617 (DRUG), SoC (DRUG).
Who is sponsoring clinical trial NCT05985655?
This trial is sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05985655 being conducted?
This trial has 12 study locations across Michigan, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.